DDInter1294 DDInter1676
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Nilutamide {u} (Compound) resembles {v} (Compound) Flutamide
Nilutamide {u} (Compound) treats {v} (Disease) prostate cancer
Nilutamide {u} (Compound) binds {v} (Gene) POR
Nilutamide {u} (Compound) is included by {v} (Pharmacologic Class) Androgen Receptor Antagonists
Nilutamide {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Nilutamide (Compound) resembles Flutamide (Compound)
Nilutamide (Compound) treats prostate cancer (Disease)
Nilutamide (Compound) binds POR (Gene)
Nilutamide (Compound) is included by Androgen Receptor Antagonists (Pharmacologic Class)
Nilutamide (Compound) causes Ill-defined disorder (Side Effect)